Initiate and dose oxycodone-with-naloxone CR tablets as for oxycodone CR tablets. People already receiving single-ingredient.
Discuss the Targin consumer medicine information (CMI) leaflet with the patient.
People receiving long-term higher-dose opioid treatment can initially experience opioid withdrawal symptoms when switching to oxycodone-with-naloxone CR tablets. 2 In key trials the incidence of withdrawal symptoms was low and similar for oxycodone-with-naloxone CR tablets and oxycodone CR tablets. 7.
‡ All trial participants had fewer than three complete spontaneous bowel movements per week at recruitment.
Online via the Therapeutic Goods Administration Online and interactive.
Oxycodone-with-naloxone controlled-release (CR) tablets (Targin) contain a combination of a strong opioid and an opioid antagonist in a controlled-release formulation.
View FDA-Approved Full Prescribing Information for OxyContin For patients taking ≥1 opioid, calculate the approx oxycodone dose for each opioid and sum.
Elderly Reduce starting dose to 1/3 to 1/2 the recommended dose in debilitated, opioid-intolerant patients.
From Other Opioids: D/C all other around-the-clock opioids when therapy is initiated and initiate dosing using 10mg q12h.
Absorption: Oral bioavailability (60-87%). Administration of variable doses resulted in different parameters. Distribution: V d =2.6L/kg (IV); plasma protein binding (45%); crosses placenta; found in breast milk. Metabolism: Extensive; via CYP3A mediated N-demethylation to noroxycodone and CYP2D6 mediated O-demethylation to oxymorphone; noroxycodone and noroxymorphone (major metabolites).
Personalized Oxycodone Dosing: Using Pharmacogenetic Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase.
Volume 15, Issue 5, pages 791–806, May 2014 Additional Information.
*Reprint requests to: Oscar A. Linares, MD, Plymouth Pharmacokinetic Modeling Study Group, Mathematical Medicine and Biostatistics Unit, 46425 Southview Lane, Plymouth, MI 48170, USA. ; ;
Studies were performed in silico.
Conflict of Interest Disclosure: No conflicts of interest.
Linares, O. A., Daly, D., Linares, A. D., Stefanovski, D. and Boston, R. C. (2014), Personalized Oxycodone Dosing: Using Pharmacogenetic Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase Effectiveness.
Dear Editor,. It is with great interest that we read the article by Linares and colleagues, “Personalized oxycodone dosing: using.
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired. Advanced Browse all 17 :4 Current Advance access.
It is with great interest that we read the article by Linares and colleagues, “Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness”, published in the April 2014 issue of Pain Medicine. The authors concluded that “By expressing a patient’s CYP2D6 phenotype pharmacokinetically, a clinician (at least theoretically) can improve the safety and efficacy of oxycodone and decrease the risk for iatrogenically induced overdose or death”.
Online calculator to convert equianalgesic doses of opioid narcotic analgesics.
When switching between opioids, equianalgesic conversions may overestimate the potency of the new opioid due to incomplete cross-tolerance. Incomplete cross-tolerance can occur due to variability in opioid binding. There is no evidence-based recommendation for an appropriate reduction. The American Pain Society guidelines and most pain experts recommend a dose reduction between 25-50% when converting between different opioids, 9, 11 with a consideration for little or no cross-tolerance reduction in patients with poorly controlled pain.